Last reviewed · How we verify

NCT07296549

Expert Consensus on the Clinical Management of Melasma: A Delphi Method Study

ENROLLING BY INVITATION Last updated 29 December 2025
What this trial tests

trial in Melasma in 15 participants. Enrolling by invitation.

Timeline
1 June 2026
Primary endpoint
1 September 2026
30 December 2026

Quick facts

Lead sponsorVenus Research Center
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment15
Start date1 June 2026
Primary completion1 September 2026
Estimated completion30 December 2026
Sites1 location across Egypt

Conditions studied

Sponsor

Venus Research Center

Who can join

25 and older, any sex, with Melasma or Melasma (Facial Melasma). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to gather expert opinions on the best ways to treat and manage melasma, a common skin condition characterized by dark patches on the face. Using a method called the Delphi Method, a group of dermatologists and other specialists will participate in several rounds of surveys to share their insights and reach a consensus on the most effective treatments and management strategies. The goal is to create a set of evidence-based guidelines that can help doctors provide more consistent, effective care for patients with melasma. The study will ensure that all experts' opinions are anonymous, and the results will be shared to improve treatment practices worldwide.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Melasma

Currently open trials in the same condition.

Other Venus Research Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07296549.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing